PetMed Express Inc (PETS)
NASDAQHealth CareSpecialty RetailSnapshot 2026-11-04
$1.24+3.33%
Close 2026-11-04 · 1-day change
NASDAQHealth CareSpecialty RetailSnapshot 2026-11-04
QuarterlyIQ Insights · PETS
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -60.6% |
| Our one-year growth estimate | diamond | -7.0% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 53.6 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Elevated risk of a next-quarter earnings miss: this name is on a run of consecutive earnings misses and has been missing across recent quarters. A fundamental tilt, not a price call.
Model as of 2026-11-04 · Compared with 11 industry peers
PETS — CEO transition
Dated 2026-09-17
CEO — Jeffrey Allen Willard: The filing announces the appointment of an external candidate as CEO and President to succeed the interim CEO, which is a significant management change but not a departure of a sitting executive.
Why it matters: Management said lower prescription sales drove much of the Q1 sales drop. A turn in these sales would ease that pressure.
Supportive ifThe November 10 report says prescription drug sales rose from a year ago.
Worry ifThe November 10 report says prescription drug sales fell from a year ago again.
Why it matters: Q1 sales fell 19.9%, led by fewer prescription sales. A smaller drop would show that sales are stabilizing.
Supportive ifIn the November 10 results, net sales fall less than 19.9% year over year, or rise.
Worry ifIn the November 10 results, net sales fall 19.9% or more year over year.
Why it matters: Management said the deal would strengthen its balance sheet and fund key plans. The results will show whether it did so.
Watch forA company filing says the sale closed and names the cash proceeds. It also says planned work continues.
Also watch forA company filing reports a delay or cancellation, or says key plans were paused after the deal.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$150 on $10,000 · ±1.5% | How much price usually moves either way. |
| Bad day | $480 loss on $10,000 · 4.8% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $7,051 loss on $10,000 · 70.5% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.